Education
About Us
Working with TipRanks
Follow Us
Perseus Proteomics, Inc. (JP:4882)
:4882
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥203.00 - ¥1,113.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥3.38B
Enterprise Value¥1.99B
Total Cash (Recent Filing)¥1.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta2.03
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.42
Shares Outstanding14,749,600
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.33
Price to Sales (P/S)87.24
P/FCF Ratio-13.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially reduces refinancing and interest-rate risk, giving management flexibility to allocate cash to R&D and operations. Over the next several months this improves financial stability and lowers default risk, extending runway versus leveraged peers.
Very High Gross MarginsConsistently very high gross margins point to strong unit economics and pricing power in the company’s proteomics products/services. This durable advantage supports potential operating leverage as revenue scales, increasing the chance of sustainable profitability if operating expenses are managed.
Positive Revenue Growth TrendOngoing revenue growth demonstrates persistent market demand for protein/antibody technologies and services. Over a multi-month horizon, sustained top-line expansion combined with high gross margins creates a credible path to improving operating margins, assuming fixed-cost discipline and scaling efficiencies.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow shows the business consumes real cash to sustain operations, forcing reliance on external financing or equity raises. This structural cash burn increases dilution and refinancing risk across the coming months absent material revenue growth or cost reduction.
Severe Net Losses And MarginsAn extreme negative net margin indicates the cost base far exceeds revenue, meaning profitability remains a distant prospect. Structurally large losses require either rapid revenue scale-up or significant cost restructuring to correct, raising the prospect of ongoing capital needs and operational uncertainty.
Eroding Equity And Negative ROEDeclining shareholders' equity and persistently negative ROE reflect capital erosion from operating losses, limiting the company’s internal ability to fund growth. Over months this constrains strategic flexibility, raises probability of dilutive financing, and signals challenges restoring capital efficiency without structural improvement.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥203.00 and its highest was ¥1113.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥3.38B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is May 08, 2026 which is in 80 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on Feb 13, 2026. The company reported -¥11.42 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.42.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 14,749,600 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.966%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Oncolys BioPharma, Inc.
―
FunPep Company Limited
―
Modalis Therapeutics Corporation
―
Kringle Pharma, Inc.
―
Cyfuse Biomedical K.K.
―